[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2020, Vol. 42 ›› Issue (9): 832-846.doi: 10.16288/j.yczz.19-381

• Review • Previous Articles     Next Articles

Advances in genome-wide association study of chronic obstructive pulmonary disease

Guoqing Qian1,2,3   

  1. 1. Department of General Internal Medicine, Ningbo First Hospital, Ningbo University, Ningbo 315010, China
    2. Department of Respiratory Medicine, Ningbo Hospital of Zhejiang University, Ningbo 315010, China
    3. Shool of Medicine, University of Nottingham, Nottingham UK NG7 2RD, UK
  • Received:2020-02-25 Revised:2020-05-29 Online:2020-09-20 Published:2020-06-19
  • Supported by:
    Supported by the Natural Science Foundation of Zhejiang Province No(Q17H010001);the Natural Science Foundation of Ningbo City No(2017A610246)

Abstract:

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and chronic airway inflammation, caused by a combination of environmental and genetic factors. It is the third leading cause of death worldwide. In recent years, researchers have applied the genome-wide association study (GWAS) and identified a large number of genetic variants associated with lung functions and potential drug targets for treating COPD. In this review, we summarize the results of GWAS studies and perform a review of the literature since 2007 to highlight the progress of GWAS on COPD. We discuss the challenges, the underlying mechanisms, and the possible drug targets, thereby providing insights on the pathogenesis and potential treatment strategies for COPD.

Key words: chronic obstructive pulmonary disease, lung function, genome-wide association study, genetic variant, locus, susceptibility gene, causal gene